Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Kristian Wiggert advises companies, financial institutions and investment funds in Europe and the US on complex cross-border transactions.  Having practiced in London since 2000, he understands the commercial issues clients face when they operate internationally.  According to Chambers UK (2014-2015) he is "very knowledgeable” and has “an eye for the legal as well as the commercial side of a transaction."  He is "good at handling novel problems quickly and efficiently and tailoring his advice to the needs of individual clients."

  • Advised Cantor Fitzgerald Europe and RBC Capital Markets as joint bookrunners on the £15 million follow-on financing structured as a placing by UK-based biopharmaceutical company, Mereo BioPharma Group plc.
  • Advised Pharming Group N.V., a Dutch publicly-traded pharmaceutical company ("Pharming"), on a new $100 million secured debt facility with OrbiMed Advisors, LLC ("OrbiMed").
  • Advised Wilmcote Holdings plc on its admission to AIM and £15 million placing of ordinary shares. 
  • Advised Vernalis plc on its acquisition of the US rights to MOXATAG® (amoxicillin extended-release tablets) from Pragma Pharmaceuticals, LLC. 
  • Advised Horizon Discovery Group plc, an AIM listed international life science company supplying research tools and services to organizations engaged in genomics research and the development of personalized medicines, on:

Memberships and Affiliations

  • American Bar Association
  • Chambers UK, Corporate/M&A: Mid-Market (2012-2015)
  • Legal 500 UK, Flotations: Small and Mid-Cap (2014, 2016)    
  • Legal 500 UK, Equity Capital Markets (2013, 2016)
  • Legal 500 UK, M&A - Premium Deals (2012-2014)
  • Legal 500 UK, Pharmaceuticals & Biotechnology (2012)